Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings Limited announced that its subsidiary, United Biotechnology, has received an upfront payment of $180 million from Novo Nordisk under an exclusive license agreement for UBT251, a triple agonist in clinical trials for obesity and type 2 diabetes. This agreement also allows United Biotechnology to potentially receive up to $1.8 billion in milestone payments and tiered royalties based on future sales, highlighting a significant financial and strategic boost for the company in the pharmaceutical sector.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing and producing medications, with a particular emphasis on treatments for obesity, type 2 diabetes, and other related diseases.
Average Trading Volume: 15,405,063
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.11B
For a thorough assessment of 3933 stock, go to TipRanks’ Stock Analysis page.